AU2017294969B2 - Heteroaromatic modulators of the retinoid-related orphan receptor gamma - Google Patents

Heteroaromatic modulators of the retinoid-related orphan receptor gamma Download PDF

Info

Publication number
AU2017294969B2
AU2017294969B2 AU2017294969A AU2017294969A AU2017294969B2 AU 2017294969 B2 AU2017294969 B2 AU 2017294969B2 AU 2017294969 A AU2017294969 A AU 2017294969A AU 2017294969 A AU2017294969 A AU 2017294969A AU 2017294969 B2 AU2017294969 B2 AU 2017294969B2
Authority
AU
Australia
Prior art keywords
methyl
phenyl
oxadiazol
amino
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017294969A
Other languages
English (en)
Other versions
AU2017294969A1 (en
Inventor
Alan Stuart JESSIMAN
Patrick Stephen Johnson
Kristoffer Maansson
Morten Dahl Sørensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of AU2017294969A1 publication Critical patent/AU2017294969A1/en
Application granted granted Critical
Publication of AU2017294969B2 publication Critical patent/AU2017294969B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
AU2017294969A 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma Ceased AU2017294969B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020268 2016-07-13
EP16020268.5 2016-07-13
PCT/EP2017/067390 WO2018011201A1 (en) 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Publications (2)

Publication Number Publication Date
AU2017294969A1 AU2017294969A1 (en) 2019-01-17
AU2017294969B2 true AU2017294969B2 (en) 2021-03-25

Family

ID=56511303

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017294969A Ceased AU2017294969B2 (en) 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Country Status (21)

Country Link
US (2) US10662181B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7016344B2 (cg-RX-API-DMAC7.html)
KR (1) KR102490140B1 (cg-RX-API-DMAC7.html)
CN (1) CN109476653B (cg-RX-API-DMAC7.html)
AU (1) AU2017294969B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000486A2 (cg-RX-API-DMAC7.html)
CA (1) CA3030370A1 (cg-RX-API-DMAC7.html)
DK (1) DK3484880T3 (cg-RX-API-DMAC7.html)
ES (1) ES2834009T3 (cg-RX-API-DMAC7.html)
IL (1) IL264141B (cg-RX-API-DMAC7.html)
MX (1) MX383770B (cg-RX-API-DMAC7.html)
MY (1) MY196990A (cg-RX-API-DMAC7.html)
PL (1) PL3484880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3484880T (cg-RX-API-DMAC7.html)
RU (1) RU2771280C2 (cg-RX-API-DMAC7.html)
SA (1) SA519400868B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201811107WA (cg-RX-API-DMAC7.html)
UA (1) UA123330C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018011201A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808436B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771280C2 (ru) * 2016-07-13 2022-04-29 Лео Фарма А/С Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма
CN111825654A (zh) * 2019-04-19 2020-10-27 北京酷瓴生物技术有限公司 苯甲烯哌啶衍生物及其制备方法、中间体和用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086894A1 (en) * 2012-12-06 2014-06-12 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2015180613A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180614A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180612A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS244821B2 (en) * 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
FR2879381B1 (fr) 2004-12-15 2008-12-26 Thales Sa Systeme de distribution quantique de cle de cryptage a variables continues
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
EP2511275A1 (en) 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
WO2015067575A1 (en) * 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag 5,6,7,8-tetrahydro-5,8-methanocinnoline derivatives as rorc modulators for the treatment of autoimmune diseases
RU2771280C2 (ru) * 2016-07-13 2022-04-29 Лео Фарма А/С Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086894A1 (en) * 2012-12-06 2014-06-12 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2015180613A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180614A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180612A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Also Published As

Publication number Publication date
UA123330C2 (uk) 2021-03-17
RU2771280C2 (ru) 2022-04-29
US20190284177A1 (en) 2019-09-19
CA3030370A1 (en) 2018-01-18
US20200291010A1 (en) 2020-09-17
US10934282B2 (en) 2021-03-02
ZA201808436B (en) 2020-05-27
ES2834009T3 (es) 2021-06-16
SA519400868B1 (ar) 2022-06-13
MX383770B (es) 2025-03-14
PL3484880T3 (pl) 2021-04-06
IL264141B (en) 2021-09-30
PT3484880T (pt) 2020-12-07
RU2019103883A (ru) 2020-08-13
NZ749301A (en) 2021-03-26
US10662181B2 (en) 2020-05-26
EP3484880B1 (en) 2020-09-02
JP2019521137A (ja) 2019-07-25
JP7016344B2 (ja) 2022-02-04
IL264141A (en) 2019-02-28
MY196990A (en) 2023-05-17
SG11201811107WA (en) 2019-01-30
CN109476653A (zh) 2019-03-15
WO2018011201A1 (en) 2018-01-18
KR20190026872A (ko) 2019-03-13
CN109476653B (zh) 2022-04-22
RU2019103883A3 (cg-RX-API-DMAC7.html) 2020-09-23
BR112019000486A2 (pt) 2019-04-24
MX2019000361A (es) 2019-05-23
EP3484880A1 (en) 2019-05-22
AU2017294969A1 (en) 2019-01-17
KR102490140B1 (ko) 2023-01-19
DK3484880T3 (da) 2020-11-09

Similar Documents

Publication Publication Date Title
CA3157177C (en) Compounds containing the pyran moiety
JP7491900B2 (ja) Tlr7/8アンタゴニストおよびそれらの使用
CA2992408A1 (en) Substituted aza compounds as irak-4 inhibitors
EA031223B1 (ru) Соединения, которые ингибируют белок mcl-1
CA3110436C (en) High activity sting protein agonist
US10934282B2 (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
EP3929188A1 (en) Pd-l1 antagonist compound
AU2020413555B2 (en) PD-L1 antagonist compound
AU2016323254B2 (en) Non-steroidal glucocorticoid receptor modulators for local drug delivery
NZ749301B2 (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
JP2017502070A (ja) RORcモジュレーターとしてのヘテロアリールスルタム誘導体
HK40005345A (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired